NASDAQ:CVAC CureVac Q2 2025 Earnings Report $5.40 0.00 (0.00%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$5.38 -0.02 (-0.37%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CureVac EPS ResultsActual EPS-$0.30Consensus EPS -$0.15Beat/MissMissed by -$0.15One Year Ago EPSN/ACureVac Revenue ResultsActual Revenue$1.41 millionExpected Revenue$4.27 millionBeat/MissMissed by -$2.86 millionYoY Revenue GrowthN/ACureVac Announcement DetailsQuarterQ2 2025Date8/21/2025TimeBefore Market OpensConference Call DateFriday, August 15, 2025Conference Call Time4:00PM ETUpcoming EarningsCureVac's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) CureVac Earnings HeadlinesCureVac’s Strategic Moves and Financial Highlights in 2025August 26 at 3:38 AM | msn.comCureVac sees cash runway into 2028August 16, 2025 | msn.comThis stock could leave NVDA in the dustInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.August 27 at 2:00 AM | InvestorPlace (Ad)CureVac reports Q2 revenue EUR 1.2M vs. EUR 14.4M last yearAugust 16, 2025 | msn.comCureVac Reports Financial Losses in Mid-2025August 16, 2025 | msn.comCureVac settles patent dispute litigation with Pfizer and BioNTechAugust 7, 2025 | reuters.comSee More CureVac Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email. Email Address About CureVacCureVac (NASDAQ:CVAC), a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.View CureVac ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Upcoming Earnings Autodesk (8/28/2025)Marvell Technology (8/28/2025)Canadian Imperial Bank of Commerce (8/28/2025)Dell Technologies (8/28/2025)Toronto Dominion Bank (8/28/2025)Alibaba Group (8/29/2025)Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access